News Releases

Date Title and Summary View
Feb 13, 2024
– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – CAMBRIDGE, Mass.
Feb 02, 2024
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 42,000 shares of
Displaying 21 - 22 of 22
Back to top